U.S. Markets closed

Novartis’s Innovative Medicines Segment in Q2 2018

Mike Benson
Novartis’s Innovative Medicines Segment in Q2 2018

Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. The segment contributed 67.4% of Novartis’s total revenues in the second quarter and reported a 10% growth YoY (year-over-year) at $8.9 billion.